ClinicalTrials.gg
CompletedNCT04856085MARCHUpdated Apr 23, 2026

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

A Phase 2 interventional study of VIR-2218 and VIR-3434 in Hepatitis B, Chronic, sponsored by Vir Biotechnology, Inc.. Completed at 37 sites in 12 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Vir Biotechnology, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
244
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Hepatitis B, Chronic with a site in Taiwan — 3 open to participants now, 10 under way, 1 of them phase 3. Hepatitis B, Chronic · Taiwan.

Enrollment
24th of 88
244 · median 120
Started
2021
with 6 others
Phase 2
26 of 99
1 open now
Registered
77th of 99
by date

Among the 99 studies in Hepatitis B, Chronic with a site in Taiwan, this one is the 24th largest by enrollment of the 88 interventional ones that give a count, is one of 7 that started in 2021, is one of 26 in phase 2, and was the 77th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 99 studies in Hepatitis B, Chronic with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Hepatitis B, Chronic with a site in Taiwan, or all of them as a file.
02

Study summary

This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy

03

Conditions studied

  • Hepatitis B, Chronic

Keywords

  • Hepatitis B Virus
  • Chronic Hepatitis B
  • HBV
  • Hepatitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ages 18 - \<66 years
  • Chronic infection for >/= 6 months
  • On NRTI therapy for >/= 2 months at the time of screening

Exclusion criteria

Exclusion Criteria:

  • Any chronic or acute medical condition that makes the participant unsuitable for participation
  • Significant fibrosis or cirrhosis
  • History or evidence of drug or alcohol abuse
  • History of chronic liver disease from any cause other than chronic infection
  • History of hepatic decompensation
  • History of anaphylaxis
  • History of allergic reactions, , or intolerance to monoclonal antibodies, antibody fragments, or any of VIR-3434
  • History of immune complex disease
  • History of known to any interferon product
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    Cohort 1a (VIR-2218 + VIR-3434)

    Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total

    Drug: VIR-2218 · Drug: VIR-3434

  • Experimental
    Cohort 2a (VIR-2218 + VIR-3434)

    Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total

    Drug: VIR-2218 · Drug: VIR-3434

  • Experimental
    Cohort 3a (VIR-2218 + VIR-3434)

    Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks

    Drug: VIR-2218 · Drug: VIR-3434

  • Experimental
    Cohort 4a (VIR-2218 + VIR-3434)

    Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks

    Drug: VIR-2218 · Drug: VIR-3434

  • Experimental
    Cohort 5a (VIR-2218 + VIR-3434)

    Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks

    Drug: VIR-2218 · Drug: VIR-3434

  • Experimental
    Cohort 6a (VIR-2218 + VIR-3434)

    Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks

    Drug: VIR-2218 · Drug: VIR-3434

  • Experimental
    Cohort 7a (VIR-2218 + VIR-3434)

    Participants will receive multiple doses of VIR-2218 + VIR-3434 for 44 weeks

    Drug: VIR-2218 · Drug: VIR-3434

  • Experimental
    Cohort 8a (VIR-2218 + VIR-3434)

    Participants will receive multiple doses of VIR-2218 + VIR-3434 for 20 weeks

    Drug: VIR-2218 · Drug: VIR-3434

  • Experimental
    Cohort 1b (VIR-3434)

    Participants will receive multiple doses of VIR-3434 for 44 weeks

    Drug: VIR-3434

  • Experimental
    Cohort 2b (VIR-3434)

    Participants will receive multiple doses of VIR-3434 for 20 weeks

    Drug: VIR-3434

  • Experimental
    Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)

    Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 24 weeks

    Drug: VIR-2218 · Drug: VIR-3434 · Drug: PEG-IFNα

  • Experimental
    Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)

    Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 48 weeks

    Drug: VIR-2218 · Drug: VIR-3434 · Drug: PEG-IFNα

  • Experimental
    Cohort 1d (VIR-3434 + PEG-IFNα)

    Participants will receive multiple doses of VIR-3434 + PEG-IFNα for 48 weeks

    Drug: VIR-3434 · Drug: PEG-IFNα

Interventions

  • VIR-2218 given by subcutaneous injection

    Also known as: Elebsiran

  • VIR-3434 given by subcutaneous injection

    Also known as: Tobevibart

  • PEG-IFNα given by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Proportion of participants with treatment-emergent adverse events (TEAEs)

    Time frame: Up to 72 weeks

  2. Proportion of participants with serious adverse events (SAEs)

    Time frame: Up to 72 weeks

  3. Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatment

    Time frame: Up to 48 weeks

  4. Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatment

    Time frame: Up to 72 weeks

Secondary outcomes

  1. Absolute serum HBsAg and change from baseline across all timepoints in the study

    Time frame: Up to 110 weeks

  2. Nadir and maximum reduction of serum HBsAg from baseline

    Time frame: Up to 110 weeks

  3. Proportion of participants achieving sustained suppression of HBV DNA (< lower limit of quantification (LLOQ) for >= 24 weeks after discontinuation of all treatment, including NRTIs)

    Time frame: Up to 110 weeks

  4. For hepatitis B e-antigen (HBeAg)-positive participants: Proportion of participants with HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion at any timepoint

    Time frame: Up to 110 weeks

  5. For HBeAg-positive participants: Time to HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion

    Time frame: Up to 110 weeks

  6. Cmax

    Time frame: Up to 110 weeks

  7. AUClast

    Time frame: Up to 110 weeks

  8. t1/2

    Time frame: Up to 110 weeks

  9. CL/F

    Time frame: Up to 110 weeks

  10. Number of participants with incidence and titers of anti-drug antibody (ADA) (if applicable) to VIR-3434

    Time frame: Up to 110 weeks

  11. Proportion of participants meeting criteria for nucleotide reverse transcriptase inhibitors (NRTI) discontinuation

    Time frame: Up to 60 weeks

  12. Proportion of participants meeting criteria for NRTI retreatment

    Time frame: Up to 110 weeks

  13. Proportion of participants achieving undetectable HBsAg and sustained suppression of HBV DNA [below the LLOQ, target not detected (TND)] >/= 24 weeks after discontinuation of all treatment, including NRTIs

    Time frame: Up to 110 weeks

  14. Proportion of participants with serum HBsAg < 10 IU/mL at end of treatment

    Time frame: Up to 48 weeks

  15. Proportion of participants with serum HBsAg < 10 IU/mL at 24 weeks post-end of treatment

    48 weeks treatment + 24 weeks post-end of treatment

    Time frame: Up to 72 weeks

  16. Proportion of participants with anti-HBs seroconversion

    Time frame: Up to 110 weeks

  17. Time to achieve nadir of serum HBsAg

    Time frame: Up to 110 weeks

  18. Time to achieve serum HBsAg loss

    Time frame: Up to 110 weeks

07

Study locations

37 sites
  • Investigative Site
    San Francisco, California 94143, United States
  • Investigative Site
    Miami, Florida 33136, United States
  • Investigative Site
    Orlando, Florida 32803, United States
  • Investigative Site
    Baltimore, Maryland 21218, United States
  • Investigative Site
    Hillsborough, New Jersey 08844, United States
  • Investigative Site
    Toronto, 2C4, Canada
  • Investigative Site
    Toronto, 3M1, Canada
  • Investigative Site
    Vancouver, 2C7, Canada
  • Investigative Site
    Frankfurt, 60590, Germany
  • Investigative Site
    Hanover, 30625, Germany
  • Investigative Site
    Mannheim, 68167, Germany
  • Investigative Site
    Hong Kong, Shatin, Hong Kong
  • Investigative Site
    Hong Kong, Tai Po District, Hong Kong
  • Investigative Site
    Hong Kong, Hong Kong
  • Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Investigative Site
    Chisinau, MD 2025, Moldova
  • Investigative Site
    Auckland, 1010, New Zealand
  • Investigative Site
    Auckland, 2025, New Zealand
  • Investigative Site
    Hamilton, 3204, New Zealand
  • Investigative Site
    Tauranga, 3110, New Zealand
  • Investigative Site
    Wellington, 6021, New Zealand
  • Investigative Site
    Bucharest, 021105, Romania
  • Investigative Site
    Busan, 49421, South Korea
  • Investigative Site
    Seoul, 03080, South Korea
  • Investigative Site
    Seoul, 05505, South Korea
  • Investigative Site
    Yangsan, 50612, South Korea
  • Investigative Site
    Chiayi City, 60041, Taiwan
  • Investigative Site
    Kaohsiung City, 80756, Taiwan
  • Investigative Site
    Kaohsiung City, 83301, Taiwan
  • Investigative Site
    Taichung, 40705, Taiwan
  • Investigative Site
    Taipei, 100, Taiwan
  • Investigative Site
    Taoyuan City, 33305, Taiwan
  • Investigative Site
    Kyiv, 01135, Ukraine
  • Investigative Site
    Birmingham, B15 2TH, United Kingdom
  • Investigative Site
    London, E11FR, United Kingdom
  • Investigative Site
    London, SE5 9RS, United Kingdom
  • Investigative Site
    Manchester, M8 5RB, United Kingdom
08

References and documents

Publications

  • Noack J, Anglero-Rodriguez Y, Gall J, Zhou J, LeBlanc S, Liebow A, Bakardjiev A, Hebner CM, Purcell LA, Jadhav V, Corti D, Lempp FA. Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models. Antimicrob Agents Chemother. 2026 Mar 4;70(3):e0112725. doi: 10.1128/aac.01127-25. Epub 2026 Jan 26. PubMed 41586499 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Mar 2026, 56 months.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 56 months is above that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Apr 22, 2021
StartActual
Jul 11, 2021
Primary completionActual
Mar 16, 2026
CompletionActual
Mar 16, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04856085
Responsible party
Sponsor
First posted
Apr 22, 2021
Start date
Jul 11, 2021
Primary completion
Mar 16, 2026
Completion
Mar 16, 2026
Last update
Apr 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tobevibart

Start the discussion